A Phase 2 interventional study of Functional Magnetic Resonance Imaging (fMRI) and Magnetic Resonance Spectroscopy (MRS) in Attention Deficit Hyperactivity Disorder (ADHD) and Impulsive Aggression, sponsored by Supernus Pharmaceuticals, Inc.. Terminated at 3 sites in United States. Open to participants aged 8 Years to 12 Years. Per ClinicalTrials.gov, last updated 2025-05-02.
Sponsored by Supernus Pharmaceuticals, Inc. · Phase 2, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Attention Deficit Disorder with Hyperactivity by Supernus Pharmaceuticals, Inc. — 1 open to participants now, 2 under way, 1 of them phase 3. Attention Deficit Disorder with Hyperactivity · Supernus Pharmaceuticals, Inc..
Among the 22 studies in Attention Deficit Disorder with Hyperactivity by Supernus Pharmaceuticals, Inc., this one is the 20th largest by enrollment, is one of 3 that started in 2019, is one of 5 in phase 2, and was the 16th registered.
1,818 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →1 of the 22 studies in Attention Deficit Disorder with Hyperactivity by Supernus Pharmaceuticals, Inc. is open now, in 1 country. Recruiting first, the newest first:
Supernus Pharmaceuticals, Inc. · Sites in United States
Ages 48 mo–69 mo
By country, each count listing its studies:
Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 8 Years to 12 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 12 · Phase 4 3
First in 2008; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 7 is below the median of 71 across 1,437 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 192 across the 22 interventional studies. Of the 19 that completed or were terminated, 16 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
Supernus Pharmaceuticals, Inc. is the lead sponsor of 64 studies on the registry; 6 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 26 (81%) have results posted.
1 of the studies in Attention Deficit Disorder with Hyperactivity by Supernus Pharmaceuticals, Inc. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02736656Phase 3Supernus Pharmaceuticals, Inc.Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Attention Deficit Disorder with Hyperactivity by Supernus Pharmaceuticals, Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate the effect of 4-week SPN-810 treatment on brain functioning in patients aged 8-12 years with ADHD and associated feature of impulsive aggression (IA). This was achieved using functional magnetic resonance imaging (fMRI) in conjunction with the point subtraction aggression paradigm (PSAP) Task, a behavioral aggression paradigm in which subjects are provoked by having money indirectly taken from them by a fictitious opponent, simulating an aggression response.
Approximately 30 subjects aged 8-12 diagnosed with ADHD and associated feature of IA were recruited in this study. The PSAP is a behavioral aggression test used to evaluate behavioral response related to impulsive aggression. The task was combined with functional MRI to evaluate the change in brain activity measured as BOLD signal (blood oxygenation level-dependent) from baseline to the end of the treatment with SPN-810.
The level of neurotransmitters Glutamate and GABA were also measured using magnetic resonance spectroscopy (MRS).
Additionally, the improvement and severity in impulsive aggression behaviors were assessed using validated scales.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects were randomized to receive SPN-810 18 mg twice a day twice each day with and without food, in addition to the stable dose of the optimized ADHD medication.
Diagnostic Test: Functional Magnetic Resonance Imaging (fMRI) · Diagnostic Test: Magnetic Resonance Spectroscopy (MRS) · Behavioral: Point Subtraction Aggression Paradigm (PSAP) Task · Drug: SPN-810
Subjects were randomized to receive Placebo twice a day twice each day with and without food, in addition to the stable dose of the optimized ADHD medication.
Diagnostic Test: Functional Magnetic Resonance Imaging (fMRI) · Diagnostic Test: Magnetic Resonance Spectroscopy (MRS) · Behavioral: Point Subtraction Aggression Paradigm (PSAP) Task · Drug: Placebo
Neural brain activity measured by fMRI
Glutamate and GABA levels measured by MRS
Aggression score measured by the PSAP task
Treatment of SPN-810 (36 mg) on neuronal brain activity, GABA and Glutamate levels and on the aggression score
Treatment of placebo on neuronal brain activity, GABA and Glutamate levels and on the aggression score
Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP Task
The primary endpoint was the aggression-related change in the whole brain in BOLD signal fMRI contrast in response to the PSAP task. BOLD fMRI contrast (neural activation) investigates brain activity by measuring the change in blood oxygenation. Change in brain activity was measured by a change in BOLD response in brain regions during the aggressive response relative to the monetary response, where the aggression was defined as the number of Option 2 presses (aggressive response) divided by the total number of button presses and the number of provocations. Change of aggression-related MRI signal was acquired at baseline and 4 weeks after SPN-810 treatment. A positive number represents an increase in activity. Region of interest is described by the location of the peak value and described by Montreal Neurological Institute (MNI) X, Y, Z coordinates. Data represent the post-treatment minus baseline change in BOLD contrast Aggressive Response\> Monetary Response.
Time frame: Baseline/Visit 2 (Day -5) to Visit 5 (Day 28) for a total of 4 weeks.
Provocation Event - Related Change in the Whole Brain in BOLD Signal fMRI Contrast in Response to the PSAP Task
BOLD (blood oxygenation level-dependent) fMRI contrast (neural activation) investigates brain activity by measuring the change in blood oxygenation. It was collected during the PSAP behavioral task while playing the game: the participants play a computer game in which they can steal points (simulating an aggressive behavior) or have points stolen by the opponent (provocation event) by pressing Option 1, 2 or 3 on a keypad a set number of times to achieve a specific outcome. A positive number represents an increase in activity. The region of interest is described by the location of the peak value within that cluster and described by Montreal Neurological Institute (MNI) X, Y, and Z coordinates. Data represent the post-treatment minus baseline change in BOLD contrast Provocation Event \>Monetary Response.
Time frame: Baseline/Visit 2 (Day -5) to Visit 5 (Day 28) for a total of 4 weeks.
Effect of SPN-810 on the Aggressions Score
The Point Subtraction Aggression Paradigm (PSAP) is a behavioral aggression paradigm consisting of a computer game in which each participant plays against a computer to earn points. The subject can steal points (i.e., aggressive behavior) or have points stolen by the opponent (i.e., provocation). The subject can press 1 of 3 buttons on a keypad a set number of times. By pressing the button for Option 1, 100 times, the subject will earn a point; pressing the button for Option 2, 20 consecutive times is the "aggression" action that results in stealing a point from the opponent; pressing Option 3, 20 times protects the subject from the opponent's attempt to steal points (i.e., money). The aggression score is averaged across two sessions and calculated as the number of Option 2 button presses divided by the sum of total button presses and the number of provocation events received, with a range minimum = 1, maximum = 143. The higher scores reflect increased aggression.
Time frame: Baseline/Visit 2 (Day -5) to Visit 5 (Day 28) for a total of 4 weeks.
Effect of SPN-810 on GABA and Glutamate Levels Using Magnetic Resonance Spectroscopy (MRS)
GABA and Glutamate concentrations (mM) were measured in the anterior cingulate cortex using magnetic resonance spectroscopy (MRS). Data represent the change from Baseline (Visit 2) to Visit 5.
Time frame: Baseline/Visit 2 (Day -5) to Visit 5 (Day 28) for a total of 4 weeks.
Effect of SPN-810 on Impulsive Aggression Measured by the Clinical Global Impression-Severity (CGI-S) Scale
The Clinical Global Impression - Severity of Illness (CGI-S) is a single item clinician rating of clinician's assessment of the severity of IA behaviors. CGI-S was evaluated by the Investigator on a 7- point scale with 1=Normal, 2=Borderline ill, 3=Mildly ill, 4=Moderately ill, 5=Markedly ill, 6=Severely ill, and 7=Extremely ill. Data represent the change between Baseline (Visit 1/Day -30) and two time points: Visit 4 (Day 21) and Visit 6 (Day 35).
Time frame: From Visit 1 (Day -30) to two time points: Visit 4 (Day 21) and Visit 6 (Day 35).
Effect of SPN-810 on Impulsive Aggression Measured by the Clinical Global Impression-Improvement (CGI-I) Scale
The Clinical Global Impression - Improvement Scale (CGI-I) is an assessment of how much the patient's illness has improved or worsened relative to a baseline state at the beginning of treatment. CGI-I was evaluated by the Investigator on a 7-point scale with 1=very much improved, 2= much improved, 3= minimally improved, 4= no change, 5= minimally worse, 6= much worse, 7= very much worse.
Time frame: Visit 4 (Day 21) and Visit 6 (Day 35), for a total of 2 weeks.
Effect of SPN-810 on the Retrospective-Modified Overt Aggression Scale (R-MOAS) Score
R-MOAS scale gauges the severity of aggressive behavior: the frequency of the 16 behaviors is rated over the past week in 4 areas (a-d). For each open question in each area, the parent rates the aggressive behaviors on a scale from 0 to 5 or more times. To each area corresponds a weighted category: 1(a), 4(b), 2(c) and 3(d). Therefore, the sum of each area yields a maximum weighted score of 20 (a), 120 (b), 60 (c) and 90 (c). The total score is the sum of the four area scores or 0-290, the higher the score, the more severe the aggressive behavior is. Data represent the change from baseline at each visit.
Time frame: Visit 1 (Day -30) to Visit 4 (Day 21) and Visit 6 (Day 35).
A multi-center, double-blind, randomized (1:1), placebo-controlled, parallel-group, 2-arm study
| Milestone | Placebo | High Dose SPN-810 (36 mg) |
|---|---|---|
| Started | 4 | 3 |
| Randomized population | 4 | 3 |
| Completed population | 4 | 2 |
| Completed | 4 | 2 |
| Not completed | 0 | 1 |
| Withdrew: Early termination | 0 | 1 |
The primary endpoint was the aggression-related change in the whole brain in BOLD signal fMRI contrast in response to the PSAP task. BOLD fMRI contrast (neural activation) investigates brain activity by measuring the change in blood oxygenation. Change in brain activity was measured by a change in BOLD response in brain regions during the aggressive response relative to the monetary response, where the aggression was defined as the number of Option 2 presses (aggressive response) divided by the total number of button presses and the number of provocations. Change of aggression-related MRI signal was acquired at baseline and 4 weeks after SPN-810 treatment. A positive number represents an increase in activity. Region of interest is described by the location of the peak value and described by Montreal Neurological Institute (MNI) X, Y, Z coordinates. Data represent the post-treatment minus baseline change in BOLD contrast Aggressive Response\> Monetary Response.
| Voxels | SPN-810 (36 mg) > Placebo | Placebo > SPN-810 (36 mg) |
|---|---|---|
| Inferior Occipital Gyrus/Cerebellum: Montreal Neurological Institute coordinates -29.5, 62.5, -4.5 | 353 (310.6 to 395.4) | 0 (0 to 0) |
| Right Fusiform Gyrus/Inferior Occipital Cortex: Montreal Neurological Institute 32.5, 52.5, 23.5 | 258 (223.1 to 292.9) | 0 (0 to 0) |
| Left Angular Gyrus (WM): Montreal Neurological Institute coordinates 4.5, 84.5, 35.5 | 173 (145.2 to 200.8) | 0 (0 to 0) |
| Left Cuneus: Montreal Neurological Institute coordinates -23.5, 96.5, 5.5 | 145 (124.6 to 165.4) | 0 (0 to 0) |
| Right Middle Occipital Gyrus: Montreal Neurological Institute coordinates -1.5, 64.5, 57.5 | 133 (114.2 to 151.8) | 0 (0 to 0) |
| Medial Precuneus: Montreal Neurological Institute coordinates -33.5, 34.5, 47.5 | 128 (111.3 to 144.7) | 0 (0 to 0) |
| Right Postcentral Gyrus: Montreal Neurological Institute coordinates -29.5, 62.5, -4.5 | 110 (95.1 to 124.9) | 0 (0 to 0) |
| Superior Medial Frontal Gyrus: Montreal Neurological Institute coordinates 2.5, -47.5, 39.5 | 0 (0 to 0) | 329 (288.6 to 369.4) |
| Right Cerebellum: Montreal Neurological Institute coordinates: -35.5, 72.5, -40.5 | 0 (0 to 0) | 175 (145.2 to 204.8) |
| Right Superior/Middle Frontal Gyrus: Montreal Neurological Institute coordinates -37.5, -33.5, 33.5 | 0 (0 to 0) | 164 (136.2 to 191.8) |
| Right Insula Montreal Neurological Institute coordinates -39.5, -13.5, -0.5 | 0 (0 to 0) | 140 (116.4 to 163.6) |
| Right Inferior Temporal Gyrus: Montreal Neurological Institute coordinates -41.5, -7.5, -46.5 | 0 (0 to 0) | 145 (124.6 to 165.4) |
| Left Postcentral Gyrus: Montreal Neurological Institute coordinates 30.5, 30.5, 51.5 | 0 (0 to 0) | 110 (95.1 to 124.9) |
BOLD (blood oxygenation level-dependent) fMRI contrast (neural activation) investigates brain activity by measuring the change in blood oxygenation. It was collected during the PSAP behavioral task while playing the game: the participants play a computer game in which they can steal points (simulating an aggressive behavior) or have points stolen by the opponent (provocation event) by pressing Option 1, 2 or 3 on a keypad a set number of times to achieve a specific outcome. A positive number represents an increase in activity. The region of interest is described by the location of the peak value within that cluster and described by Montreal Neurological Institute (MNI) X, Y, and Z coordinates. Data represent the post-treatment minus baseline change in BOLD contrast Provocation Event \>Monetary Response.
| Voxels | SPN-810 (36 mg) > Placebo | Placebo > SPN-810 (36 mg) |
|---|---|---|
| Right Postcentral Gyrus: Montreal Neurological Institute coordinates: -31.5, 30.5, 43.5 | 318 (276.3 to 359.7) | 0 (0 to 0) |
| Left Middle/Inferior Temporal Gyrus: Montreal Neurological Institute coordinates 52.5, 16.5, -24.5 | 137 (117.5 to 156.5) | 0 (0 to 0) |
| Medial Cerebellum: Montreal Neurological Institute coordinates: 12.5, 50.5 -32.5 | 0 (0 to 0) | 123 (104.1 to 141.9) |
| Left Inferior Frontal Gyrus: Montreal Neurological Institute coordinates: 42.5, -15.5, 19.5 | 0 (0 to 0) | 122 (105.0 to 139.0) |
| Right Cerebellum: Montreal Neurological Institute coordinates: -23.5, 70.5, -24.5 | 0 (0 to 0) | 109 (94.4 to 123.6) |
The Point Subtraction Aggression Paradigm (PSAP) is a behavioral aggression paradigm consisting of a computer game in which each participant plays against a computer to earn points. The subject can steal points (i.e., aggressive behavior) or have points stolen by the opponent (i.e., provocation). The subject can press 1 of 3 buttons on a keypad a set number of times. By pressing the button for Option 1, 100 times, the subject will earn a point; pressing the button for Option 2, 20 consecutive times is the "aggression" action that results in stealing a point from the opponent; pressing Option 3, 20 times protects the subject from the opponent's attempt to steal points (i.e., money). The aggression score is averaged across two sessions and calculated as the number of Option 2 button presses divided by the sum of total button presses and the number of provocation events received, with a range minimum = 1, maximum = 143. The higher scores reflect increased aggression.
| score on a scale | Placebo | High Dose SPN-810 (36 mg) |
|---|---|---|
| Baseline/Visit 2 | 8.43 ± 9.22 | 10.23 ± 6.21 |
| Visit 5 | 9.26 ± 5.50 | 4.02 ± 2.60 |
GABA and Glutamate concentrations (mM) were measured in the anterior cingulate cortex using magnetic resonance spectroscopy (MRS). Data represent the change from Baseline (Visit 2) to Visit 5.
| mM | Placebo | High Dose of SPN-810 (36 mg) |
|---|---|---|
| GABA (mM) | 0.79 ± 0.26 | 0.75 ± 0.67 |
| Glutamate (mM) | 0.78 ± 2.44 | 0.23 ± 1.91 |
The Clinical Global Impression - Severity of Illness (CGI-S) is a single item clinician rating of clinician's assessment of the severity of IA behaviors. CGI-S was evaluated by the Investigator on a 7- point scale with 1=Normal, 2=Borderline ill, 3=Mildly ill, 4=Moderately ill, 5=Markedly ill, 6=Severely ill, and 7=Extremely ill. Data represent the change between Baseline (Visit 1/Day -30) and two time points: Visit 4 (Day 21) and Visit 6 (Day 35).
| score on a scale | Placebo | High Dose SPN-810 |
|---|---|---|
| Visit 4 | -1.25 ± 1.5 | -1.5 ± 2.12 |
| Visit 6 | -2.25 ± 1.5 | -1.5 ± 2.12 |
The Clinical Global Impression - Improvement Scale (CGI-I) is an assessment of how much the patient's illness has improved or worsened relative to a baseline state at the beginning of treatment. CGI-I was evaluated by the Investigator on a 7-point scale with 1=very much improved, 2= much improved, 3= minimally improved, 4= no change, 5= minimally worse, 6= much worse, 7= very much worse.
| score on a scale | Placebo | High Dose of SPN-810 (36 mg) |
|---|---|---|
| Visit 4 | 2.3 ± 1.26 | 1.5 ± 0.71 |
| Visit 6 | 2.3 ± 1.26 | 1.0 ± 0.0 |
R-MOAS scale gauges the severity of aggressive behavior: the frequency of the 16 behaviors is rated over the past week in 4 areas (a-d). For each open question in each area, the parent rates the aggressive behaviors on a scale from 0 to 5 or more times. To each area corresponds a weighted category: 1(a), 4(b), 2(c) and 3(d). Therefore, the sum of each area yields a maximum weighted score of 20 (a), 120 (b), 60 (c) and 90 (c). The total score is the sum of the four area scores or 0-290, the higher the score, the more severe the aggressive behavior is. Data represent the change from baseline at each visit.
| score on a scale | Placebo | High Dose SPN-810 (36 mg) |
|---|---|---|
| Visit 4 | -52.0 ± 30.23 | -43.0 ± 2.83 |
| Visit 6 | -61.0 ± 18.81 | -39.5 ± 24.75 |
Collected over Visit 3 (Day 1) to Visit 6 (Week5)-End of Study, a total of 5 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| High Dose SPN-810 | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| Event | Placebo | High Dose SPN-810 |
|---|---|---|
| Decrease appetiteMetabolism and nutrition disorders | 2/4 | 0/3 |
| Blood Prolactin IncreasedInvestigations | 0/4 | 1/3 |
| FatigueGeneral disorders | 1/4 | 0/3 |
Randomized Population: The Randomized Population consists of all enrolled subjects who completed the Baseline Period including imaging scans, meet the inclusion/exclusion criteria and were randomized to SPN-810 36 mg or Placebo.
| Age, Categorical(Participants) | Placebo | High Dose SPN-810 (36 mg) | Total |
|---|---|---|---|
| <=18 years | 4 | 3 | 7 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Placebo | High Dose SPN-810 (36 mg) | Total |
|---|---|---|---|
| Mean | 9.5 ± 1.29 | 11.3 ± 1.15 | 10.3 ± 1.50 |
| Sex: Female, Male(Participants) | Placebo | High Dose SPN-810 (36 mg) | Total |
|---|---|---|---|
| Female | 0 | 2 | 2 |
| Male | 4 | 1 | 5 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | High Dose SPN-810 (36 mg) | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 2 | 4 |
| Not Hispanic or Latino | 2 | 1 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | High Dose SPN-810 (36 mg) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 3 |
| White | 2 | 1 | 3 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Region of Enrollment(participants) | Placebo | High Dose SPN-810 (36 mg) | Total |
|---|---|---|---|
| United States | 4 | 3 | 7 |
| Vitiello Aggression Total Score(units on a scale) | Placebo | High Dose SPN-810 (36 mg) | Total |
|---|---|---|---|
| Mean | -3.5 ± 1.29 | -3.7 ± 1.53 | -3.6 ± 1.27 |
| Retrospective-Modified Overt Aggression Scale (R-MOAS) Total Score(units on a scale) | Placebo | High Dose SPN-810 (36 mg) | Total |
|---|---|---|---|
| Mean | 102.5 ± 32.30 | 57.0 ± 6.00 | 83.0 ± 33.54 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2019 to primary completion in Nov 2019, 5 months.
Results were first posted in May 2025, 5 years 5 months after primary completion. A results delay was requested in Jan 2021.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Molindone
Attention Deficit Disorder with Hyperactivity →
Supernus Pharmaceuticals, Inc. →